問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Neurology

China Medical University Hospital-Taipei (在職)

Division of Neurology

更新時間：2023-09-19

楊玉婉Yang, Yu-Wan
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 10 個月

Recruiting Trial

16Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊玉婉

List

42Cases

2020-01-01 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2012-05-01 - 2018-12-03

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2023-09-01 - 2024-02-17

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2012-01-01 - 2013-12-31

Phase II

A PHASE 2 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF PF-03049423 IN SUBJECTS WITH ISCHEMIC STROKE

  • Condition/Disease

    ISCHEMIC STROKE

  • Test Drug

    PF-03049423

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

2014-02-01 - 2016-01-31

Phase III

Acute Stroke Or Transient IsChemic Attack TReated with Aspirin or Ticagrelor and Patient OutcomES

  • Condition/Disease

    Patients with an acute cerebral ischemic event (minor stroke/high-risk TIA) and high risk of subsequent ischemic stroke, who could be randomised within 24 hours of symptom onset

  • Test Drug

    Ticagrelor

Participate Sites
11Sites

Terminated10Sites

Study ended1Sites

林瑞泰
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2018-01-22 - 2019-12-31

Phase III

A Randomized, Double-Blinded, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack

  • Condition/Disease

    Acute Ischemic Stroke or Transient ischaemic attack

  • Test Drug

    BRILINTA

Participate Sites
16Sites

Recruiting15Sites

Study ended1Sites

李宗海
Linkou Chang Gung Medical Foundation

Division of Neurology

林秀芬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2013-10-01 - 2017-12-31

Phase III

An Open-Label Two-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects with Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment with Available Anti-Parkinsonian Medications

  • Condition/Disease

    Available Anti-Parkinsonian Medications

  • Test Drug

    ABT-SLV187 (Duodopa)

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

蔡崇豪
China Medical University Hospital

Division of Neurology

2013-07-01 - 2015-12-31

Phase III

An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects with Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment with Available Anti Parkinsonian Medications

  • Condition/Disease

    Available Anti Parkinsonian Medications

  • Test Drug

    ABT-SLV187 (Duodopa)

Participate Sites
3Sites

Terminated3Sites

2013-05-20 - 2018-12-31

Phase III

A multicenter, double-blind, placebo-controlled, randomised, parallel-group phase 3 study to evaluate the safety and efficacy of masitinib in patients with mild to moderate Alzheimer’s disease.

  • Condition/Disease

    mild to moderate Alzheimer’s disease

  • Test Drug

    masitinib

Participate Sites
6Sites

Terminated6Sites

2019-12-01 - 2020-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy

  • Condition/Disease

    Drug-Resistant Epilepsy/Focal-Onset Seizures

  • Test Drug

    Padsevonil

Participate Sites
8Sites

Terminated8Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB